On September 15, 2023, PhenomeX made a groundbreaking announcement about their latest innovation, the Meteor chips. These chips are specifically designed for quantitative bulk analysis on the IsoSpark platform, aiming to revolutionize high throughput multiplexed hands-free proteomics.
The introduction of the Meteor chip solution has opened up new possibilities for researchers. It allows them to conduct high throughput proteomic analysis with unparalleled efficiency. Not only that, but it also enables fully quantitative bulk and comprehensive single cell proteomics on the IsoSpark platform.
PhenomeX is a renowned company in the field of functional cell biology. Their primary focus is to provide researchers with efficient workflows and unique data insights. Their ultimate goal is to make the cells and proteome accessible to every laboratory.
One of the standout features of the IsoSpark platform is its predictive immune response. This feature allows for quality assessments of cell immunotherapies, leading to improved assessment of clinical response. This advancement has the potential to revolutionize the field of immunotherapy and significantly impact patient outcomes.
Overall, PhenomeX’s unveiling of the Meteor chips and their integration into the IsoSpark platform marks a significant milestone in the world of proteomics. With these advancements, researchers can expect enhanced efficiency, accuracy, and accessibility in their proteomic analyses. This breakthrough technology has the potential to drive major advancements in the field of functional cell biology and improve patient care.
CELL
Updated on: 15/09/2023
Financial Health
Neutral
Debt to equity ratio:
Price to earnings ratio:
Price to book ratio:
DCF:
ROE:
CELL Stock Analysis: Earnings Growth, Revenue, and Financial Performance Updates
On September 15, 2023, CELL stock opened at $0.98 and fluctuated between $0.98 and $0.99 throughout the day. The total volume of shares traded was 360,815, lower than the average volume over the past three months. The market capitalization of CELL is $97.3 million. The company’s earnings growth for the previous year was -32.40%, but the current year is projected to have a growth of +31.81%. The projected earnings growth for the next five years is +4.00%. CELL’s revenue growth for the previous year was -7.96%. The P/E ratio for CELL stock is not available (NM), and the price/sales ratio is 2.35. The price/book ratio is 0.50. There is no available data on CELL’s competitors. The next reporting date for CELL is scheduled for November 16, 2023, when the company will release its financial results for the current quarter. Analysts forecast an EPS of -$0.23 for this quarter. In the previous year, CELL reported annual revenue of $78.6 million and a net loss of -$98.0 million. The net profit margin was -124.74%. CELL operates in the Technology Services sector and is part of the Packaged Software industry. Investors should closely monitor CELL’s financial performance and upcoming quarterly reports.
CELL Stock Analysis: Steady Performance and Earnings Loss in Q3 for PhenomeX Inc
CELL stock, representing PhenomeX Inc, has shown steady performance according to the 12-month price forecasts provided by four analysts. The median target price is 1.00, with a high estimate and a low estimate also at 1.00. This indicates that the analysts expect a +1.72% increase from the last recorded price of 0.98 on September 15, 2023.
The consensus among six polled investment analysts is to hold the stock in PhenomeX Inc. This rating has remained unchanged since August, suggesting that there is no significant change in the overall sentiment towards the stock.
Looking at the financial performance of PhenomeX Inc in the current quarter, the company reported an earnings per share of -$0.23. This indicates a loss for the quarter.
In terms of sales, PhenomeX Inc reported $20.6 million for the current quarter.
Investors and analysts will be eagerly awaiting the reporting date of November 16 to gain more insights into PhenomeX Inc’s financials. This report will provide a more comprehensive picture of the company’s performance and help investors make informed decisions.
It is crucial to consider other factors beyond the provided information when evaluating CELL stock. Factors such as industry trends, competitive landscape, and overall market conditions can significantly impact the stock’s performance. Therefore, it is advisable for investors to conduct thorough research and consult with financial professionals before making any investment decisions.
Discussion about this post